Egta
Egta has been studied in 2 papers since 2022: none in people yet, 1 in animals, 1 in cells; 1 in the past year. The research so far is in animals and cells. The newest paper, Oct 20, 2026: “Complex antiarrhythmic effects of empagliflozin in non-ischemic HFrEF cardiomyocytes”.
1 new paper in 30 daysSee all 2 papers on egta
At a glance
The findings reach worms or flies, none yet in people; independent labs found the same change in worms or flies. 4 independent labs in 1 country.
1 of its findings points the other way.
- 4 independent labs in 1 country
- 1 finding against
- Funders: American Heart Association and 8 more
- Model organisms1
- Cells1
What did lifespan studies of egta find?
DrugAgeDrugAge records 2 results from 2 papers: 1 in A. brightwelli and 1 in M. brevispina. Average lifespan is the mean or the median, as each paper reports it.
What did studies of egta find?
3Studies of egta measured 3 outcomes; the most studied are delayed afterdepolarizations (1 study), amyloid beta aggregation (1) and lifespan (1).
Delayed afterdepolarizations
downin mouse cells1downin rabbit cells1
1 study
Delayed afterdepolarizations
downin mouse cells1downin rabbit cells1
Egta prevents delayed afterdepolarizations in mouse cells (non-ischemic, non-diabetic HFrEF; intracellular Ca2+ buffering).
“Intracellular Ca2+ buffering with EGTA prevented DADs, attenuated APD prolongation, and reduced repolarization instability.”
Cellsnon-ischemic, non-diabetic HFrEF; intracellular Ca2+ bufferingventricular cardiomyocyte
Complex antiarrhythmic effects of empagliflozin in non-ischemic HFrEF cardiomyocytes
Frontiers in pharmacology
Egta prevents delayed afterdepolarizations in rabbit cells (non-ischemic, non-diabetic HFrEF; intracellular Ca2+ buffering).
“Intracellular Ca2+ buffering with EGTA prevented DADs, attenuated APD prolongation, and reduced repolarization instability.”
Cellsnon-ischemic, non-diabetic HFrEF; intracellular Ca2+ bufferingventricular cardiomyocyte
Complex antiarrhythmic effects of empagliflozin in non-ischemic HFrEF cardiomyocytes
Frontiers in pharmacology
Amyloid beta aggregation
downin worms1
1 study
Amyloid beta aggregation
downin worms1
Egta decreases amyloid beta aggregation in Aβ-induced C. elegans AD models.
“Both EGTA and nimodipine showed remarkable inhibitory effects on Aβ 1−42 aggregations by increasing oxidative stress resistance.”
Model organismsin Aβ-induced C. elegans AD models
Oxidative medicine and cellular longevity
Lifespan
upin worms1
1 study
Lifespan
upin worms1
Egta extends lifespan in Aβ-induced C. elegans AD models.
“Moreover, both compounds significantly delayed the onset of Aβ-induced paralysis, rescued memory deficits, ameliorated behavioral dysfunction, decreased the vulnerability of two major (GABAergic and dopaminergic) neurons and synapses, and extended the lifespan of the C. elegans AD models.”
Model organismsin Aβ-induced C. elegans AD models
Oxidative medicine and cellular longevity